Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study

The primary purpose of this study is to assess the efficacy and safety of THVD-201(Combination of tolterodine and pilocarpine) in patients with Overactive bladder during the period of treatment, 12 weeks.
This study also includes an open label extension period of an additional 12 weeks following the treatment to assess long-term efficacy and safety of THVD-201 in patients with Overactive bladder.

开始日期2015-01-01

申办/合作机构

SK Chemicals Co. Ltd.

NCT01036035 / Completed临床1期

Effects of THVD-201 on Pharmacokinetics and Pharmacodynamics of Tolterodine in Healthy Subjects

THVD-201 is a novel combination of a muscarinic antagonist (tolterodine) and a muscarinic agonist (pilocarpine).

开始日期2009-09-01

申办/合作机构

TheraVida, Inc.

100 项与毛果芸香碱/托特罗定相关的临床结果

登录后查看更多信息

100 项与毛果芸香碱/托特罗定相关的转化医学

登录后查看更多信息

100 项与毛果芸香碱/托特罗定相关的专利（医药）

登录后查看更多信息

项与毛果芸香碱/托特罗定相关的文献（医药）

2016-07-02·Expert Opinion on Pharmacotherapy3区 · 医学

Current and future pharmacotherapy for treating overactive bladder

3区 · 医学

Review

作者: Robinson, Dudley ; Thiagamoorthy, Ganesh ; Cardozo, Linda

INTRODUCTIONDrugs which prevent acetylcholine mediated involuntary detrusor contractions are the mainstay of overactive bladder(OAB) treatment but there are now several alternative therapeutic options available.AREAS COVEREDCurrent and future drug therapies for OAB are highlighted. These include novel antimuscarinic molecules (imidafenacin and tarafenacin); novel combination therapies with β3-adrenoceptor agonists or muscarinic agonists (tolenix) and a novel vaginal delivery method for oxybutynin. β3-adrenoceptor agonists(β3-AR) have been shown to be efficiacious in the management of OAB. The evidence supporting the first licensed β3-AR agonist, mirabegron, is assessed, as well as other putative β3-AR agonists in development such as solabegron, ritobegron, aryloxypropanolamine, TRK-380, and CL 316,243. The role of vaginal oestrogen is highlighted followed by a detailed analysis of botulinum-A toxin.EXPERT OPINIONAnticholinergics were the first OAB drug therapy on the market and have the largest dataset available. Despite obvious limitations, these are still first line medical therapy. There are a number of new OAB therapies under investigation and we await their contribution to the management armamentarium. Other novel drugs have been licenced and these are now vying for pole position in the treatment algorithm. One must exercise caution however until the long term effects of any new medicines are known.

2014-10-01·Expert Opinion on Investigational Drugs2区 · 医学

Phase II drugs that target cholinergic receptors for the treatment of overactive bladder

2区 · 医学

Review

作者: Ilias Giarenis ; Martino Maria Zacche ; Linda Cardozo

INTRODUCTIONOveractive bladder (OAB) is a term used to describe the symptom syndrome of urgency, with or without urgency incontinence, usually associated with frequency and nocturia. Antimuscarinics are the most widely prescribed class of drugs for OAB, although their systemic adverse effects limit their use in clinical practice as compliance. This has led to developments in the field.AREAS COVEREDIn this review, the authors describe Phase II drugs that target cholinergic receptors. First, the authors present the new antimuscarinics (tarafenacin and afacifenacin). This is followed by reports on a combination drug (tolenix) containing a muscarinic antagonist (tolterodine) associated with a muscarinic agonist (pilocarpine). Further, the authors discuss the trials of well-known drugs in either new combination therapy (solifenacin and mirabegron) or with new routes of delivery (oxybutynin vaginal ring). Finally, the authors examine the option of targeting nicotinic acetylcholine receptors (dexmecamylamine).EXPERT OPINIONDifferent strategies have been adopted to improve the efficacy and tolerability of therapeutics for OAB. Nicotinic receptors represent a novel therapeutic target; however, it is unlikely that antimuscarinic agents will be replaced as standard first-line therapy in the near future.

100 项与毛果芸香碱/托特罗定相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膀胱过度活动症	临床3期	韩国	SK Chemicals Co. Ltd.	2015-01-01
膀胱过度活动症	临床3期	韩国	SK Chemicals Co. Ltd.	2015-01-01
尿失禁	临床3期	-	TheraVida, Inc.	2009-09-01